2023
Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study
Ehrlich H, Somé A, Bazié T, Ebou C, Dembélé E, Balma R, Goodwin J, Wade M, Bei A, Ouédraogo J, Foy B, Dabiré R, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. The Lancet Microbe 2023, 4: e461-e469. PMID: 37086737, PMCID: PMC10365133, DOI: 10.1016/s2666-5247(23)00063-0.Peer-Reviewed Original ResearchConceptsMosquito blood mealsAntimalarial drug resistanceSurvey 3Blood-fed mosquitoesBlood samplesSurvey 1Survey 2Blood mealDrug resistanceUltrasensitive quantitative PCRHuman blood samplesCross-sectional studyMargin of equivalenceStrong surveillance systemCross-sectional surveySupplementary Materials sectionMarker of clonalityPragmatic thresholdAntimalarial resistanceDrug susceptibilityInfectious diseasesPlasmodium falciparumNational InstituteTolerabilityMaterial section
2017
Modelling the impact of antimalarial quality on the transmission of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum
Brock AR, Ross JV, Greenhalgh S, Durham DP, Galvani A, Parikh S, Esterman A. Modelling the impact of antimalarial quality on the transmission of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Infectious Disease Modelling 2017, 2: 161-187. PMID: 29928735, PMCID: PMC6001968, DOI: 10.1016/j.idm.2017.04.001.Peer-Reviewed Original ResearchAntimalarial usePoor-quality antimalarial medicinesAntimalarial medicinesSulfadoxine-pyrimethamine resistanceDrug-resistant parasitesEradication of malariaHuman malaria casesAntimalarial qualitySP monotherapySubtherapeutic dosesTransmission of resistanceMalaria casesDeterministic compartmental modelEffective treatmentResistant parasitesSP resistanceElimination effortsMalaria controlPlasmodium falciparumMonotherapyMedicine qualityPoor qualityTreatmentMedicineCompartmental model
2005
Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors
Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrobial Agents And Chemotherapy 2005, 49: 2983-2985. PMID: 15980379, PMCID: PMC1168637, DOI: 10.1128/aac.49.7.2983-2985.2005.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1Protease inhibitorsHuman immunodeficiency virus type 1 (HIV-1) protease inhibitorsImmunodeficiency virus type 1HIV-1 protease inhibitorsVirus type 1Antimalarial activityCultured Plasmodium falciparumDevelopment of parasitesLopinavir therapyType 1Malaria parasitesPlasmodium falciparumLopinavirRelevant concentrationsInhibitorsPotent compoundsSimilar concentrationsParasitesRitonavirTherapyActivityFalciparum